Oruka Therapeutics, Inc. (ORKA) NASDAQ
64.06
+3.92(+6.52%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
64.06
+3.92(+6.52%)
Currency In USD
Address
221 Crescent Street Building 23, Suite 105
Menlo Park, MA
United States of America (the)
Phone
203-554-7604
Website
Sector
Healthcare
Industry
Biotechnology
Employees
28
First IPO Date
August 08, 1997
| Name | Title | Pay | Year Born |
| Lawrence Otto Klein | President, Chief Executive Officer & Director | 1.08M | 1983 |
| Joana Goncalves | Chief Medical Officer | 730,980 | 1974 |
| Paul T. Quinlan | General Counsel & Secretary | 730,980 | 1963 |
| Rajiv Panwar | Senior VP and Head of Chemistry, Manufacturing & Controls | 0 | N/A |
| Alan Lada | VP of IR & Capital Markets | 0 | N/A |
| Arjun Agarwal | Senior Vice President of Finance & Treasurer | 0 | 1976 |
| Christopher Finch | Senior VP and Head of Business Development & Strategy | 0 | N/A |
| Laura Sandler | Chief Operating Officer | 0 | 1978 |
Oruka Therapeutics, Inc. functions as a biotechnology firm primarily dedicated to creating groundbreaking monoclonal antibody therapies. These treatments are designed to address Psoriasis (PsO) along with various other inflammatory and immunological (I&I) conditions. Its current development portfolio includes ORKA-001 and ORKA-002. The company's main operations are based in Menlo Park, CA.